• Нетрадиционные методы лечения вазомоторных симптомов при угасании репродуктивной и овариальной функций с позиций доказательной медицины

Нетрадиционные методы лечения вазомоторных симптомов при угасании репродуктивной и овариальной функций с позиций доказательной медицины

HEALTH OF WOMAN. 2016.10(116):37–41


Нетрадиционные методы лечения вазомоторных симптомов при угасании репродуктивной и овариальной функций с позиций доказательной медицины


Веропотвелян П. Н., Цехмистренко И. С., Веропотвелян Н. П., Гужевская И. В.

«Межобластной центр медицинской генетики и пренатальной диагностики», г. Кривой Рог

Национальный медицинский университет имени А.А. Богомольца, г. Киев

Перинатальный центр, г. Киев


В статье представлены литературные данные по нетрадиционным методам лечения за последние 5 лет. В обзоре освещаются консенсусное мнение экспертов по данной проблеме за 2015–2016 гг., результаты эффективности и безопасности немедикаментозных методов лечения, растительных и нейроактивных препаратов для терапии вазомоторных симптомов.

Проведена оценка различных методов лечения. Особое внимание уделено менопаузальной гормональной терапии. Практический врач должен быть информирован об уровне доказательств эффективности и безопасности нетрадиционных методов лечения, чтобы предотвратить недостаточное применение эффективных и, наоборот, применение неэффективных или неприемлемых для пациенток методов. Поэтому практический врач обязан в каждом конкретном случае сделать индивидуальный выбор терапии, приемлемой для пациентки.


Ключевые слова: менопаузальные симптомы, нетрадиционные методы лечения, фитоэстрогены, селективные ингибиторы обратного захвата серотонина.


Литература: 
1. Boardman H.M. Hormone therapy for preventing cardiovascular disease in post-menopausal women /L.Hartley, A. Eisinga, C. Main, M. Roque i Figuls, X. Bonfill Cosp [et al.]//Cochrane Database Syst. Rev. 2015; (3): CD002229. https://doi.org/10.1002/14651858.cd002229.pub4

2. Rossouw J.E. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy /J.E. Manson, A.M. Kaunitz, G.L. Anderson //Obstet. Gynecol. 2013; 121(1): 172–6. https://doi.org/10.1097/AOG.0b013e31827a08c8; PMid:23262943 PMCid:PMC3547645

3. Boekhout A.H. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial /A.D. Vincent, O.B. Dalesio, J. van den Bosch, J.H. Foekema-Tons, S. Adriaansz [et al.] //J. Clin. Oncol. 2011; 29(29): 3862–8. https://doi.org/10.1200/jco.2010.33.1298

4. Peng W. Critical review of complementary and alternative medicine use in menopause: focus on prevalence, motivation, decision-making, and communication /J. Adams, D.W. Sibbritt, J.E. Frawley //Menopause. 2014; 21(5): 536–48. https://doi.org/10.1097/GME.0b013e3182a46a3e; PMid:24104604

5. Gentry-Maharaj A. Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study /C. Karpinskyj, C. Glazer, M. Burnell, A. Ryan, L. Fraser [et al.]//Menopause. 2015; 22(4): 384–90. https://doi.org/10.1097/GME.0000000000000330; PMid:25290539 PMCid:PMC4470524

6. Schierbeck L.L. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial /L. Rejnmark, C.L. Tofteng, L. Stilgren, P. Eiken, L. Mosekilde [et al.] //BMJ. 2012; 345: e6409. https://doi.org/10.1136/bmj.e6409; PMid:23048011

7. Lobo R.A. The hope for KEEPS //Climacteric. 2015; 18(2): 108–9. https://doi.org/10.3109/13697137.2015.1007428; PMid:25651981

8. Hodis H.N. Vascular effects of early versus late postmenopausal treatment with estradiol /W.J. Mack, V.W. Henderson, D. Shoupe, M.J. Budoff, L. Hwang-Levine [et al.] //N. Engl. J. Med. 2016; 374(13): 1221–31. https://doi.org/10.1056/NEJMoa1505241; PMid:27028912 PMCid:PMC4921205

9. Haney E.M. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? /S.J. Warden, M.M. Bliziotes //Bone. 2010; 46(1): 13–7. https://doi.org/10.1016/j.bone.2009.07.083; PMid:19664737 PMCid:PMC3413453

10. Hayes L.P. Use of gabapentin for the management of natural or surgical menopausal hot flashes /D.G. Carroll, K.W. Kelley //Ann. Pharmacother. 2011; 45(3): 388–94. https://doi.org/10.1345/aph.1P366; PMid:21343402

11. Yureneva S.V. Alternative treatments of vasomotor symptoms in light of evidence-based medicine /L.M. Ilyinа, Z.H. Ebzeeva //Obstetrics and gynecology 2016; 6:32–38.

12. Toulis К.A. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis /T. Tzellos, D. Kouvelas, D.G. Goulis //Clin. Ther. 2009; 31(2): 221–35.

13. Smetnik V. «Non-operative gynecology» /L. Tumilovich //Moscow 2005:99.

14. Blumel J.E. Menopausal transition, physiopathology, clinical and treatment /M.N. Cruz, N.J. Aparicio //Medicina 2002; 62(l): 57–65.

15. Avis N.E. The Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition //S.L. Crawford, G. Greendale, J.T. Bromberger, S.A. Everson-Rose, E.B. Gold [et al.] //JAMA Intern. Med. 2015; 175(4): 531–9.

16. Zeleke B.M. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study /R.J. Bell, B. Billah, S.R. Davis //Fertil. Steril. 2016; 105(1): 149–55. https://doi.org/10.1016/j.fertnstert.2015.09.017

17. Stuenkel C.A. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline /S.R. Davis, A. Gompel, M.A. Lumsden, M.H. Murad, J.V. Pinkerton, R.J. Santen //Clin. Endocrinol. Metab. 2015; 100(11): 3975–4011.

18. Smetnik V.P. Menopausal hormone therapy and health preservation of women of Mature age. Clinical recommendations (treatment protocols). – M.; 2015.

19. Baber R.J. The IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy /N. Panay, A. Fenton //Climacteric. 2016; 19(2): 109–50. https://doi.org/10.3109/13697137.2015.1129166; PMid:26872610

20. Maclennan A.H. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes /J.L. Broadbent, S. Lester, V. Moore //Cochrane Database Syst. Rev.2004; (4): CD002978.

21. Rossouw J.E. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial /G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick [et al.] //JAMA. 2002; 288(3): 321–33.

22. Studd J. «PROFOX» – the post HRT nightmare //Climacteric. 2011; 14(2): 217–9. https://doi.org/10.3109/13697137.2010.529199; PMid:21105839

23. Mintziori G. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms /I. Lambrinoudaki, D.G. Goulis, I. Ceausu, H. Depypere, C.T. Erel [et al.] //Maturitas. 2015; 81(3): 410–3. https://doi.org/10.1016/j.maturitas.2015.04.009; PMid:25982505

24. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11): 1155–74.

25. Daley A. Exercise for vasomotor menopausal symptoms /H. Stokes-Lampard, A. Thomas, C. MacArthur //Cochrane Database Syst. Rev. 2014; (11): CD006108.

26. Lethaby A. Phytoestrogens for menopausal vasomotor symptoms /J. Marjoribanks, F. Kronenberg, H. Roberts, J. Eden, J. Brown //Cochrane Database Syst. Rev. 2013; (12): CD001395.

27. Li L. Quantitative efficacy of soy isoflavones on menopausal hot flashes /Y. Lv, L. Xu, Q. Zheng //Br. J. Clin. Pharmacol. 2015; 79(4): 593–604.

28. Taku K. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials /M.K. Melby, F. Kronenberg, M.S. Kurzer, M. Messina //Menopause. 2012; 19(7): 776–90. https://doi.org/10.1097/gme.0b013e3182410159; PMid:22433977

29. Schmidt M. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints /K. Arjomand-Wolkart, M.H. Birkhauser, A.R. Genazzani, D.M. Gruber, J. Huber [et al.] //Gynecol. Endocrinol. 2016; 32(6): 427–30. https://doi.org/10.3109/09513590.2016.1152240

30. Setchell K.D. Equol: history, chemistry, and formation /C. Clerici //J. Nutr. 2010; 140(7): 1355S-62S.

31. EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS). Risk assessment for peri- and postmenopausal women taking food supplements containing isolated isoflavones //EFSA J. 2015; 13(10): 4246.

32. National Institute for Health and Clinical Excellence. NICE Clinical Guideline Menopause. 2015. Available at: https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and- management-1837330217413.

33. Lipovac M. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women /P. Chedraui, C. Gruenhut, A. Gocan, C. Kurz, B. Neuber, M. Imhof //Gynecol. Endocrinol. 2012; 28(3): 203–7.

34. Edena J.A. Phytoestrogens for menopausal symptoms: a review //Maturitas. 2012; 72(2): 157–9. https://doi.org/10.1016/j.maturitas.2012.03.006; PMid:22516278

35. Leach M.J. Black cohosh (Cimicifuga spp.) for menopausal symptoms /V. Moore //Cochrane Database Syst. Rev. 2012; (9): CD007244. PMid:22972105

36. Medicines and Healthcare products Regulatory Agency (MHRA). Liver failure case highlights need to use Black Cohosh remedies carefully //MHRA Press; 2012. Available at: press.office@mhra.psi.gov.uk

37. Fritz H. Black cohosh and breast cancer: a systematic review. Integr /D. Seely, J. McGowan, B. Skidmore, R. Fernandes, D.A. Kennedy [et al.] //Cancer Ther. 2014; 13(1): 12–29. https://doi.org/10.1177/1534735413477191

38. Shechter M. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease /C.N. Merz, M. Paul-Labrador, S.R. Meisel, R.K. Rude, M.D. Molloy [et al.] //Am. J. Cardiol. 1999; 84(2): 152–6. https://doi.org/10.1016/S0002-9149(99)00225-8

39. Van Laecke S. Thrombotic microangiopathy: a role for magnesium? /E.V. Nagler, R. Vanholder //Thromb. Haemost. 2012; 107(3): 399–408. https://doi.org/10.1160/TH11-08-0593; PMid:22274299

40. Nelson H.D. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis /K.K. Vesco, E. Haney, R. Fu, A. Nedrow, J. Miller [et al.] //JAMA 2006; 295(17): 2057–71. https://doi.org/10.1001/jama.295.17.2057; PMid:16670414

41. Shams Т. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials /B. Firwana, F. Habib, A. Alshahrani, B. Alnouh, M.N. Murad, M.J. Ferwana //Gen. Intern. Med. 2014; 29(1): 204–13. https://doi.org/10.1007/s11606-013-2535-9

42. Rada G. Non- hormonal interventions for hot flushes in women with a history of breast cancer /D. Capurro, T. Pantoja, J. Corbalбn, G. Moreno, L.M. Letelier, C. Vera //Cochrane Database Syst. Rev. 2010; (9): CD004923. https://doi.org/10.1002/14651858.cd004923.pub2

43. Fisher W.I. Risk factors, pathophysiology, and treatment of hot flashes in cancer /A.K. Johnson, G.R. Elkins, J.L. Otte, D.S. Burns, M. Yu, J.S. Carpenter //CA Cancer J. Clin. 2013; 63(3): 167–92. https://doi.org/10.3322/caac.21171; PMid:23355109 PMCid:PMC3640615

44. Simon J.A. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials /D.J. Portman, A.M. Kaunitz, H. Mekonnen, K. Kazempour, S. Bhaskar, J. Lippman //Menopause. 2013; 20(10): 1027–35. https://doi.org/10.1097/GME.0b013e3182a66aa7; PMid:24045678

45. Sun Z. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials /Y. Hao, M. Zhang //Gynecol. Obstet. Invest. 2013; 75(4): 255–62. https://doi.org/10.1159/000348564

46. Joffe H. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial /K.A. Guthrie, A.Z. LaCroix, S.D. Reed, K.E. Ensrud, J.E. Manson [et al.] //JAMA Intern. Med. 2014; 174(7): 1058–66. https://doi.org/10.1001/jamainternmed.2014.1891

47. Steams V. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine /M.D. Johnson, J.M. Rae, A. Morocho, A. Novielli, P. Bhargava [et al.] //J. Natl. Cancer Inst. 2003; 95(23): 1758–64. https://doi.org/10.1093/jnci/djg108

48. Веропотвелян П.Н. Клинический поход к метаболическому синдрому в менопаузальном периоде /A.A. Тамамшева, B.В. Радченко, Н.П. Веропотвелян, Н.В. Воленко //Медицинские аспекты здоровья женщины 2015; 2 (88): 48–57.

49. Gevorkyan M.A. Modern approach to the treatment of women with pathological menopause /I.B. Manukhin [et al.] //Medical Council. 2010; 3(4): 15–20.